PharmaCyte Biotech receives Nasdaq board independence deficiency notice after director death

PharmaCyte Biotech, Inc.

Independent director Thomas C.K. Yuen passed away Feb 13, 2022, triggering noncompliance with Nasdaq Listing Rule 5605(b)(1).
Cure period: until earlier of next annual shareholders' meeting or Feb 13, 2023; if meeting before Aug 12, 2022, compliance by Aug 12, 2022.
Company expects to appoint a new independent director to regain compliance before the cure period expires.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.